Celator Pharmaceuticals (NASDAQ:CPXX) : Wednesdays money flow indicated an uptick to downtick ratio was at 3.29. The total value of inflow transactions on upticks was $0.14 million, whereas, the total value of outflow trades on downticks was $0.04 million. The total money flow was $0.1 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.01 million. The total value of the trades done on upticks was $0.01 million. Celator Pharmaceuticals (NASDAQ:CPXX) was trading with a -0.1% change over previous days close. It fell $0.03 during the day and reached $30.17. The stock was -0.07% compared to the previous weeks close.
In an insider trading activity, Morenstein Scott D, director of Celator Pharmaceuticals Inc had purchased 5,000 shares on December 3, 2015 in a transaction. The price per share was $1.87 and the total amount of the disclosed transaction was $9,350.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices. Currently the company Insiders own 9.3% of Celator Pharmaceuticals shares according to the proxy statements. Institutional Investors own 45.45% of Celator Pharmaceuticals shares.
Celator Pharmaceuticals (NASDAQ:CPXX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $30.20 and $30.17 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $30.21. The buying momentum continued till the end and the stock did not give up its gains. It closed at $30.21, notching a gain of 0.03% for the day. The total traded volume was 602,501 . The stock had closed at $30.20 on the previous day.
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing products to cure cancer. Celators technology platform, CombiPlex, offers the rational design and rapid evaluation of combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Companys products are in research and development phases. Celators lead product is CPX-351, a liposomal formulation of cytarabine:daunorubicin for the treatment of acute myeloid leukemia. The Company owns worldwide development and commercialization rights to CPX-351. The Companys other pipeline products includes CPX-1, a liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer, and a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation.